category -

Government Releases Medical Device Scheme Data; PLI Investment Reaches ₹1,153 Crore, FDI Stands at ₹17,201 Crore

Explore the latest government data on India’s medical device industry, highlighting ₹1,153.07 crore in actual investment under the Production Linked Incentive (PLI) Scheme and ₹17,201 crore in foreign direct investment (FDI) between FY2021–22 and FY2025–26. Discover key developments in the Medical Device Parks Scheme and the Scheme for Strengthening of Medical Device Industry (SMDI), including manufacturing incentives, shared infrastructure, cluster development, and support for MSMEs and startups. Learn how these initiatives aim to reduce import dependence, expand domestic manufacturing, and strengthen India’s position in the global MedTech market.

Published :

July 29, 2026

Updated :

October 28, 2026

Published :

July 29, 2026

Updated :

October 28, 2026

Government Releases Medical Device Scheme Data
India Medical Device Industry Government Scheme Update – PLI Investment Reaches ₹1,153.07 Crore, FDI Totals ₹17,201 Crore, and Medical Device Parks and SMDI Support Domestic Manufacturing, MSMEs, Innovation, and MedTech Infrastructure Development.
Table of Contents
Picture of By Operon Strategist Editorial Team
By Operon Strategist Editorial Team

Publisher
Medical Device Regulatory News and Industry Insights

In a written reply in the Lok Sabha, Union Minister for Chemicals and Fertilisers Jagat Prakash Nadda released the latest status report on key government initiatives driving India’s MedTech sector.

Highlighting progress across the Production Linked Incentive (PLI) Scheme, the Medical Device Parks Scheme, and the Scheme for Strengthening of Medical Device Industry (SMDI), the report demonstrates significant growth in domestic manufacturing, infrastructure expansion, and foreign direct investment.

Related Reads: Government Launches Incentive Scheme for Medical Device Manufacturers

Contact us for expert guidance

1. Production Linked Incentive (PLI) Scheme

  • Financial Outlay: ₹3,420 crore covering four key target segments: cancer care/radiotherapy, radiology & imaging equipment, anaesthetics/cardio-respiratory & renal care, and implants.
  • Approved Applications: 27 applications approved, including 14 from MSMEs.
  • Actual Investment & Incentives: Reported actual investment reached ₹1,153.07 crore, with ₹266.64 crore in incentives released up to FY2024–25.
  • Manufacturing Milestone: Commercial production has already commenced for high-end equipment including CT and MRI machines, linear accelerators (LINACs), mammography systems, C-arms, ultrasound systems, heart valves, and stents.

2. Medical Device Parks Scheme

  • Infrastructure Hubs: Dedicated parks are under development in Noida (Uttar Pradesh), Ujjain (Madhya Pradesh), and Kancheepuram (Tamil Nadu).
  • Facilities: Parks offer common infrastructure such as testing laboratories, sterilization units, warehousing, incubation hubs, and prototyping centers.
  • Progress: 210 manufacturing units have been allotted plots across the three locations, with ₹177.98 crore utilized out of ₹209.80 crore central assistance released.

3. SMDI Projects and Sectoral Growth

  • SMDI Outlay: ₹500 crore allocated for the FY2024–25 to FY2027–28 period.
  • Import Reduction & Clusters: 24 projects approved with ₹101.50 crore in grants under the Marginal Investment Scheme for Reducing Import Dependence (MIS-RID). An additional 13 cluster projects received approvals amounting to ₹88.67 crore.
  • MSME & Startup Push: Seven approved projects targeting high-precision instruments are being spearheaded by MSMEs, including four innovative startups.

4. Robust Foreign Direct Investment (FDI)

Foreign direct investment in India’s MedTech sector reached ₹17,201 crore between FY2021–22 and FY2025–26, reflecting mounting global confidence in India as an emerging hub for medical device manufacturing.

Ready to set up or expand your medical device unit?

Contact us to launch your project

How Operon Strategist Can Help

With government schemes like PLI, SMDI, and Medical Device Parks driving rapid expansion and investment in India’s MedTech sector, manufacturers, MSMEs, and foreign investors must align their facility planning and technical documentation with strict regulatory standards. Operon Strategist offers end-to-end consulting services to help organizations leverage these incentives, set up compliant facilities, and accelerate market access.

Our key services include:

Our team works closely with medical device manufacturers, startups, and international investors to simplify regulatory compliance, streamline plant engineering, and ensure the successful commercialization of compliant medical technologies.

Also Check: CDSCO to Reject Long-Pending Applications on SUGAM Portal After Final Reminder

Picture of  Operon Strategist Editorial Team
Operon Strategist Editorial Team

Publisher | Medical Device Regulatory News and Industry Insights
The Operon Strategist Editorial Team publishes news, updates, and insights on medical device regulations, regulatory policy changes, and global healthcare industry developments. The team covers key regulatory frameworks, including CDSCO, US FDA, EU MDR, ISO 13485, and international market access requirements, helping medical device manufacturers and healthcare businesses stay informed about evolving regulatory expectations.

Table of Contents

Subscribe Newsletter

Talk to our experts

Talk To Our Experts

Have questions about regulatory compliance? Share your requirements and our experts will help you find the right solution.